decisionhealth Newsletters, Answer Books - 2008 Issue 5 (May)
Medicare_Carriers_Manual / 4460 / 4460
Subscribe or sign in to view the full article.
Article Overview
This article covers a Medicare coverage policy for oral anti-emetic drugs used in a chemotherapy setting, with emphasis on when the drugs may be considered covered, how the therapy period is framed, and what claim-processing context is referenced. It is useful for billing staff, coders, and pharmacy or physician office personnel who need to understand the policy’s scope and the related Medicare documentation and claims requirements.
Why This Topic Matters
Understanding this policy helps providers and billing teams identify when oral anti-emetic therapy is addressed under Medicare rules and how the associated claims are expected to be represented in the referenced payment system.
Article Sections
-
4460. Payment for Oral Anti-Emetic Drugs When Used as Full Replacement for Intravenous Anti-Emetic Drugs as Part of a Cancer Chemotherapeutic Regimen
Describes the Medicare policy area covered by this manual section and the general treatment context it addresses. It also references the timing of service and the relationship to chemotherapy-related care.
What You Will Learn
- The overall Medicare policy context for oral anti-emetic drugs in a chemotherapy setting
- How the article frames the covered therapy window and prescription basis
- What claim-processing context is referenced for these drugs
- Which broader documentation and diagnosis context is mentioned for coverage review
Who Should Read This
- Medical coders
- Billing staff
- Physician office staff
- Pharmacology or pharmacy billing personnel
- Revenue cycle professionals
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com